The data was presented in a poster titled at the American Thyroid Association (ATA).
Lassen Therapeutics presented new preclinical data on LASN01, for the treatment of Thyroid Eye Disease (TED) at the American Thyroid Association (ATA).
LASN01 is a novel, fully human antibody directed against the human IL-11 receptor being developed for fibrosis. A clinical trial (NCT05331300) is evaluating the safety, tolerability, with the secondary objective evaluating the immunogenicity and pharmacokinetics of single and multiple doses of LASN01 in healthy participants and in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrosing interstitial lung disease (PF-ILD) or TED.2
“We continue our work in demonstrating the potential benefit of LASN01 in orbital fibroblasts, the relevant cell type for thyroid eye disease,” said Maria Fardis, PhD, MBA, CEO at Lassen. “In preclinical studies, LASN01 led to the suppression of cell proliferation and hyaluronan secretion from primary TED orbital fibroblasts, in addition to demonstrating anti-fibrotic activity. These results indicate that LASN01 has the potential to be a new therapeutic agent for the treatment of TED.”
The data was presented in a poster titled, “LASN01 a high affinity anti-interleukin-11 receptor antibody, blocks pathological mechanisms of thyroid eye disease linked to clinical efficacy.”
According to a press release from Lassen, the poster described how LASN01 inhibits hyaluronic acid (HA) release, proliferation, and procollagen production in response to IL-11, the combination of IL-11 and IGF-1, or TGFβ in orbital fibroblasts (OF) from TED patients following orbital decompression surgery.1
The effects of LASN01 on HA release and OF proliferation were comparable to the approved anti-IGF-1R antibody, teprotumumab, indicating that LASN01 should be further investigated as a potential new therapeutic agent for the treatment of TED, stated the company in the press release.1